Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RECT | Rectitude | $2.30 | $1.10 | 91.67% | 4.1M | $17M | $1.00$5.21 |
| BTM | Bitcoin Depot | $4.28 | $1.65 | 62.74% | 73.6K | $29M | $1.91$48.16 |
| ALMU | Aeluma | $15.50 | $4.74 | 44.01% | 11.2M | $194M | $6.08$25.88 |
| MNTS | Momentus | $4.95 | $1.47 | 42.24% | 6.7M | $20M | $3.11$43.55 |
| RVMD | Revolution Medicines | $134.54 | $38.11 | 39.52% | 401.8K | $19B | $34.00$135.81 |
| LICN | Lichen International | $4.29 | $1.10 | 34.48% | 126.7K | $52M | $2.57$8.28 |
| XNDU | Xanadu Quantum Technologies | $11.92 | $2.96 | 32.98% | 1.5M | $203M | $6.97$12.97 |
| SYRE | Spyre Therapeutics | $66.19 | $14.90 | 29.05% | 221.9K | $4.0B | $12.04$74.95 |
| HURA | TuHURA Biosciences | $2.89 | $0.62 | 27.09% | 2.7M | $144M | $0.41$4.44 |
| BNAI | Brand Engagement Network | $52.53 | $10.47 | 24.89% | 729.9K | $245M | $1.18$86.28 |
| IMA | ImageneBio | $6.02 | $1.12 | 22.81% | 17.4M | $55M | $3.94$18.00 |
| OPTX | Syntec Optics | $11.45 | $2.10 | 22.46% | 128.5K | $346M | $1.04$12.20 |
| MTC | MMTec | $7.00 | $1.28 | 22.38% | 1.4K | $570M | $0.25$7.00 |
| TBRG | TruBridge | $21.99 | $4.01 | 22.30% | 902.4K | $268M | $13.88$26.74 |
| HHS | Harte Hanks | $2.88 | $0.52 | 21.81% | 34.3K | $18M | $2.22$5.39 |
| ALLO | Allogene Therapeutics | $3.31 | $0.59 | 21.69% | 1.7M | $663M | $0.86$4.46 |
| ORCX | Tidal Trust II - Defiance Daily Target 2x Long Orcl ETF | $28.63 | $5.06 | 21.45% | 3.9M | - | $22.37$181.59 |
| ORCU | Direxion Shares ETF Trust - Daily Orcl Bull 2x Etf | $10.20 | $1.80 | 21.43% | 1.5M | - | $7.99$27.62 |
| WSHP | WeShop | $6.19 | $1.08 | 21.14% | 1.4K | $120M | $4.95$250.00 |
| HIMZ | Tidal Trust II - Defiance Daily Target 2x Long Hims ETF | $23.93 | $4.12 | 20.77% | 1M | - | $12.38$780.77 |
| CRWG | Themes ETF Trust - Leverage Shares 2x Long Crwv Daily ETF | $4.81 | $0.79 | 19.65% | 44.3M | - | $1.80$19.63 |
| MOVE | Corvex | $13.04 | $2.14 | 19.59% | 64.8K | $18M | $3.44$25.68 |
| CLLS | Cellectis | $4.29 | $0.70 | 19.50% | 5.4K | $260M | $1.33$5.48 |
| NETG | Themes ETF Trust - Leverage Shares 2x Long Net Daily ETF | $9.06 | $1.41 | 18.37% | 378.7K | - | $7.40$15.17 |
| BBNX | Beta Bionics | $10.48 | $1.62 | 18.28% | 700.2K | $393M | $8.80$32.71 |
| HCAI | Huachen Ai Parking Management Technology | $7.54 | $1.14 | 17.81% | 63.2K | $223M | $3.96$318.45 |
| CDT | Cdt Equity | $4.80 | $0.72 | 17.67% | 62.4K | $19M | $3.64$3,030.00 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $2.67 | $0.40 | 17.64% | 23.1M | - | $0.95$20.92 |
| BCG | Binah Capital Group | $2.06 | $0.30 | 17.05% | 399K | $29M | $1.36$3.44 |
| SKIL | Skillsoft | $5.30 | $0.74 | 16.29% | 151.4K | $40M | $3.43$24.01 |
| VACHU | Voyager Acquisition Corp. | $10.40 | -$1.10 | -9.56% | 1 | $329M | $10.08$14.41 |
Related Articles
Featured Article
This 2020 Biotech IPO Is Poised to Break Out in 2021
Patrick Bafuma|Apr 2, 2021
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
4 Companies That Could Upend the Pharma Industry
James Halley|Jul 29, 2020
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
Investors Scrambled to Buy This Biotech IPO
Jim Crumly|Feb 21, 2020
Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.
These Gene-Editing Pioneers Are Making Bold Bets in Agriculture
Maxx Chatsko|Jan 18, 2020
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine?
Maxx Chatsko|Dec 23, 2019
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
3 IPOs That Have More Than Tripled in 2019
Rick Munarriz|Jul 1, 2019
Beyond Meat, MMTec, and ShockWave Medical are the three hottest IPOs through the first half of this year.
2 Big Biotech Stock Upgrades: Can They Reach These Targets?
Cory Renauer|May 5, 2019
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
George Soros Bought This Under-the-Radar Biotech Stock: Should You?
George Budwell, PhD|Aug 20, 2018
Soros Fund Management picked up a healthy stake in rare-disease and cancer drugmaker Aeglea BioTherapeutics in the second quarter.
Is Cellectis SA Stock a Buy Now?
Cory Renauer|Apr 7, 2018
Despite getting passed along to a biotech start-up, Cellectis could have a bright future.
Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?
Todd Campbell|Apr 6, 2018
Belldegrun's Allogene Therapeutics has just inked a transformative deal to land Pfizer's CAR-T cancer gene therapy program.
